Intravascular Imaging Guidance for Percutaneous Coronary Intervention: Balancing Clinical Outcomes and Cost-Effectiveness Authors: Massoud A. Leesar, Mehmet Cilingiroglu Published: 2026 Coronary angiography has a major limitation for the assessment of lesion characteristics, stent optimization, and management of percutaneous coronary intervention (PCI) complications. In contrast, intravascular imaging (IVI), including intravascular ultrasound and optical coherence tomography, has a pivotal role in detecting suboptimal stent results. The preprocedural assessment of vessels by IVI provides indispensable insights into the reference vessel dimensions, lesion characteristics, calcification, and morphology, which are poorly assessed by coronary angiography. Postprocedural IVI provides detailed strut-level evaluation of stents, including stent underexpansion, geographic miss, and edge dissection.1 Stent failure is commonly linked to stent underexpansion, the impact of which on the “revascularization journey” is adverse outcomes. The poststent minimum stent area is the most consistent imaging predictor of clinical outcomes, including stent thrombosis and target vessel failure.1 Even in the contemporary era of drug-eluting stents, stent underexpansion is a common finding.2 Beyond stent expansion and optimization, IVI provides indispensable insights into the assessment and management of major PCI complications, including stent edge dissection, intramural hematoma, coronary perforation, stent thrombosis, geographic miss, and in-stent restenosis. The role of IVI for improving PCI outcomes is indisputable. As evident from large randomized clinical trials,3, 4, 5 IVI-guided PCI significantly improves stent optimization and reduces PCI complications, including target vessel failure, myocardial infarction, and stent thrombosis. This has led the 2024 European Society of Cardiology guidelines to make a strong recommendation for IVI for PCI of complex lesions (class 1).6 Likewise, the 2025 American College of Cardiology/American Heart Association guidelines have made a strong class I recommendation for IVI in patients with acute coronary syndromes undergoing PCI of the left main or complex lesions.7 Despite the evidence of benefit and guidelines, adoption of IVI in the United States and Europe remains limited and has been attributed to several factors, including the lack of routine implementation of IVI by operators during PCI, device cost, and additional procedure time. The RENOVATE-COMPLEX-PCI trial (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention)8 showed that although IVI-guided PCI was associated with higher costs than angiography-guided PCI during the 3-year follow-up period, it reduced cumulative costs and improved quality of life during lifetime simulation. This suggests that IVI-guided PCI is the clinically preferred and cost-saving option over the patients’ lifetime. In this issue of JSCAI, Kayser et al9 performed a scoping review of the literature on the cost of IVI. They performed partial economic evaluations to assess upfront procedural costs associated with IVI use, and full economic evaluations were performed to investigate longer-term cost-effectiveness using combined costs and clinical outcomes. They reported that IVI-guided PCI was associated with 10% to 30% higher upfront cost than angiography-guided PCI; however, the full economic evaluation showed that IVI was cost effective or economically dominant during follow-up. Subgroup analysis showed that IVI was particularly cost effective among patients with complex lesions, ST-segment elevation myocardial infarction, diabetes mellitus, reduced ejection fraction, and chronic kidney disease. The authors should be commended for the comprehensive literature review and analysis, providing results that address cost-effectiveness, one of the major stated obstacles of IVI use during PCI. One limitation of the study is the inclusion of abstracts rather than published peer-reviewed manuscripts exclusively; however, they circumvented this limitation by performing a sensitivity analysis of peer-reviewed manuscripts only, which demonstrated consistent results. Another limitation is predominance of available economic data are derived from studies evaluating intravascular ultrasound, with limited data specific to optical coherence tomography. Nevertheless, these data add to the growing evidence of clinical and economic benefit of IVI, and cost should not be an obstacle to its use. CRediT authorship contribution statement Massoud A. Leesar: Writing – original draft, Writing – review & editing. Mehmet Cilingiroglu: Writing – original draft, Writing – review & editing.